Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...

GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical ... In oncology, while PARP inhibitors remain relatively static, Jemperli shows promising growth, particularly in endometrial cancer ...